A review of vinorelbine in the treatment of breast cancer

G. H. Domenech, C. L. Vogel

Research output: Contribution to journalReview article

28 Scopus citations

Abstract

As combinations and sequences of anthracyclines and taxanes increasingly become standard adjuvant treatment for early breast cancer, a major need for new treatment options for metastatic breast cancer will arise. Vinorelbine is highly active in the treatment of metastatic breast cancer, both as a single agent and in combination regimens. Furthermore, it is well tolerated, with a low incidence of subjective toxicities. It is anticipated, therefore, that vinorelbine will become increasingly utilized for treating metastatic breast cancer due to its favorable safety profile, good tolerability, and promising results in combination with other chemotherapy agents. Combinations with trastuzumab and newer molecular targeting agents are being explored. Doublets or triplets of vinorelbine with drugs other than anthracyclines and taxanes could be considered in the next generation of adjuvant and neoadjuvant trials, where it is anticipated that anthracycline/taxane combinations are likely to replace anthracycline/cyclophosphamide combinations as the mainstay of adjuvant treatment.

Original languageEnglish (US)
Pages (from-to)113-128
Number of pages16
JournalClinical breast cancer
Volume2
Issue number2
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

    Fingerprint

Keywords

  • Adjuvant therapy
  • Combination therapy
  • Doxorubicin
  • Fluoropyrimidines
  • Taxanes
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research

Cite this